Archives: Agenda

In this presentation Matt will discuss strategies to optimize the design and delivery of early phase oncology trials, including:

• Dose optimisation and dose selection in early phase oncology trials
• Adaptive designs
• Accelerated titration for early cohorts
• Backfill strategies
• Biomarker analysis integration

Hear from a representative at Science4Tech on how they are advancing access to numerous technological innovations, elevating the quality, rigor, and reliability of clinical research rooted in the scientific method.

 Science4Tech Representative

• Selecting an imaging vendor
• Decentralized clinical imaging
• Multi specialist access to imaging
• Electronic data transfer
• Importance of patient data return

• Feasibility figures true to delivery
• Regulatory dynamics for strategic advantages
• Collaborate with patients and physicians to enhance access to innovative therapies
• New study designs that accelerate development programs

• Considering touchpoints of how and when we can digitally reach patients
• Collating digital patient input to incorporate their voice
• Highlighting challenges and benefits of digital patient engagement

• Reiterating basics of AI and its uses in pharma
• Identification and prioritization of suitable AI and tools
• Building a holistic AI strategy: incorporating tools, ethics and data privacy
• Creating the roadmap: challenges and lessons learnt to overcome them

Carol was diagnosed with Hodgkins Lymphoma in 2004 and her life and music career was all put on hold. She was repeatedly told that she would not survive, but now, in remission with a different blood type and new DNA, she is one of the most in-demand session musicians in the UK.

Carol will discuss her decade-long fight with cancer, her experiences with failed treatments, transplants and clinical trials and how she has faced fear head on and beaten the odds.

Project Optimus, an initiative led by the FDA’s Oncology Center of Excellence, is reshaping the landscape of oncology drug development by fundamentally altering the approach to dose optimization and dose selection. Traditionally, oncology drug trials focused on identifying the maximum tolerated dose (MTD) to ensure efficacy, often at the cost of increased toxicity. However, Project Optimus challenges this paradigm, advocating for a more nuanced approach where multiple doses are rigorously tested to find the optimal balance between efficacy, safety, and patient tolerability.

The initiative’s impact extends across various stages of drug development, from preclinical studies to pivotal Phase III trials. By emphasizing early collaboration between drug developers and the FDA, Project Optimus aims to ensure that the chosen doses not only maximize therapeutic benefit but also minimize adverse effects, thereby enhancing the overall success rate of oncology therapies.

However, this shift is not without its challenges. The need for larger, more complex trials and the incorporation of innovative trial designs, such as seamless Phase I/II studies and randomized dose-ranging trials, can increase the time and cost associated with drug development. Smaller biotech companies, in particular, may face difficulties adapting to these new requirements. Yet, the long-term benefits—more effective treatments with fewer side effects—promise to transform patient outcomes and set a new standard in oncology drug development.

Introduction

• Overview of Project Optimus and its origins within the FDA’s Oncology Center of Excellence.
• The traditional approach to dose selection in oncology (MTD-focused) and its limitations.

Key Objectives of Project Optimus

• Reforming dose optimization to focus on efficacy, safety, and tolerability.
• Encouraging early and ongoing collaboration between drug developers and the FDA.
• Integrating patient-reported outcomes (PROs) into dose-finding studies to better assess tolerability.

Impact on Early-Phase Drug Development

• Changes in Phase I and Phase II trial designs, including the move away from 3+3 dose-escalation models.
• The role of pharmacokinetic (PK) and pharmacodynamic (PD) data in dose selection.
• Case studies highlighting the successful implementation of Project Optimus guidelines (e.g., Amgen’s Lumakras, GSK’s Blenrep).

Challenges and Opportunities

• Increased trial complexity, costs, and the need for larger patient populations.
• Implications for smaller biotech companies and strategies to navigate these challenges.
• Potential long-term benefits, including improved patient outcomes and reduced trial failure rates.

The Future of Oncology Drug Development

• How Project Optimus may influence global regulatory practices.
• The evolving role of dose optimization in other therapeutic areas beyond oncology.
• Predictions for the next decade of drug development under the Project Optimus framework.

Conclusion

• Recap of the transformative impact of Project Optimus on oncology drug development.
• Final thoughts on how the industry can adapt to these changes to bring safer, more effective therapies to patients.